Skip to main content
. 2013 Mar 28;2013(3):CD005028. doi: 10.1002/14651858.CD005028.pub3

Calzavara‐Pinton 2011.

Methods DESIGN 
 Within‐patient
 Participant delivery
 ALLOCATION 
 Random
 Method of randomisation: not stated
 Concealment: unclear
 BLINDING 
 Single‐blind (investigator/outcome assessor)
 WITHDRAWAL/DROPOUT 
 Described
Participants N: 20
Treatment duration: 8 wks; FU: 16 wks
LF: 2 (10%)
BC: yes
Age: 40.2 (range = 19 to 68)
Gender (per cent men): 40%
Severity: PSI = median 8 (IQR = 7 to 9.25)
INCLUSION CRITERIA

  • Participants with mild plaque psoriasis

  • Symmetrical plaques


EXCLUSION CRITERIA

  • Not stated
Interventions

  • Budesonide 0.25 mg/g cream OM plus tacalcitol 4 mcg/g ointment ON

  • Calcipotriol 50 mcg/g and betamethasone dipropionate 0.5 mg/g once daily
Outcomes

  1. Psoriasis Severity Index (erythema + infiltration + scaling) (0 to 12)

  2. VAS (adverse events; itching): 0 to 10

  3. Patient preference and satisfaction (better/equal/worse)
Notes The sponsor was not stated.